PubRank

Gary E Gallick

Author PubWeight™ 121.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003 4.62
2 Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009 4.19
3 Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007 4.12
4 Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009 3.57
5 Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009 3.36
6 Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008 2.59
7 HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005 2.53
8 ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011 2.49
9 Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006 2.07
10 Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002 2.03
11 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
12 Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell 2007 1.97
13 Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2012 1.92
14 Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002 1.88
15 Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006 1.87
16 Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005 1.83
17 Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 2003 1.80
18 Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003 1.75
19 Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006 1.74
20 Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002 1.70
21 The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 2004 1.69
22 Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 2013 1.62
23 Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002 1.57
24 Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005 1.55
25 CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005 1.54
26 Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 2007 1.54
27 Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009 1.54
28 Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008 1.50
29 Src continues aging: current and future clinical directions. Clin Cancer Res 2007 1.50
30 Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2011 1.49
31 Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003 1.41
32 Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 2006 1.39
33 Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006 1.38
34 Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 2011 1.34
35 Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res 2005 1.34
36 SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 2007 1.32
37 Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem 2006 1.30
38 AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest 2007 1.30
39 Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis 2006 1.26
40 The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 2011 1.24
41 BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 2011 1.23
42 Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol 2011 1.23
43 GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One 2009 1.20
44 Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 2013 1.18
45 Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 2003 1.17
46 AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol 2007 1.17
47 Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 2007 1.14
48 c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005 1.14
49 AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 2005 1.13
50 Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 2010 1.12
51 Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 2008 1.10
52 Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 2007 1.10
53 The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene 2005 1.08
54 Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 2011 1.08
55 Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 2003 1.07
56 Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 2005 1.06
57 Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 2005 1.06
58 Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis 2006 1.03
59 Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 2007 1.03
60 Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 2008 1.02
61 Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res 2013 1.01
62 Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther 2005 1.01
63 Decoding the intrinsic mechanism that prohibits ALIX interaction with ESCRT and viral proteins. Biochem J 2010 0.98
64 A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol 2003 0.97
65 SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 2006 0.96
66 Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 2011 0.93
67 Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer 2013 0.92
68 Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol 2007 0.91
69 Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003 0.91
70 Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 2007 0.88
71 Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One 2012 0.88
72 A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 2012 0.87
73 A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 2012 0.86
74 Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly. EMBO J 2008 0.86
75 Src signaling pathways in prostate cancer. Cancer Metastasis Rev 2014 0.86
76 Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res 2006 0.85
77 Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res 2004 0.85
78 Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A 2010 0.83
79 Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res 2013 0.83
80 Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int J Oncol 2006 0.81
81 AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol 2010 0.80
82 Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck 2013 0.80
83 Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog 2010 0.78
84 Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate 2013 0.78
85 Proteomics profiling of exosomes from primary mouse osteoblasts under proliferation versus mineralization conditions and characterization of their uptake into prostate cancer cells. J Proteome Res 2017 0.75